On July 23, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the amendment and restatement of the employment agreement with Martin Brenner, the company's CEO and Chief Scientific Officer. The new agreement, effective as of July 1, 2024, increases Dr. Brenner's base salary to $522,365 and raises his bonus target to 50% of his base salary for fiscal year 2025, while maintaining a 40% bonus target for fiscal year 2024. Dr. Brenner's employment remains at-will, and the agreement outlines standard and additional termination benefits, including severance payments and health insurance coverage under certain conditions. The agreement also includes provisions for the assignment of inventions and non-solicitation. The amended and restated employment agreement is attached to the filing as Exhibit 10.1.

On July 23, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the amendment and restatement of the employment agreement with Martin Brenner, the company's CEO and Chief Scientific Officer. The new agreement, effective as of July 1, 2024, increases Dr. Brenner's base salary to $522,365 and raises his bonus target to 50% of his base salary for fiscal year 2025, while maintaining a 40% bonus target for fiscal year 2024. Dr. Brenner's employment remains at-will, and the agreement outlines standard and additional termination benefits, including severance payments and health insurance coverage under certain conditions. The agreement also includes provisions for the assignment of inventions and non-solicitation. The amended and restated employment agreement is attached to the filing as Exhibit 10.1.